Showing results (101-110 of 142) with videos related to

Sort By:
Pageof 15
Methods in Molecular Biology (Clifton, N.J.)|February 2, 2026
From Genome to Function: Metabolism-Wide Models of Lifecycle Stages of ParasitesBruno R Pinto, Gabriela T Montanaro, Mayke B Alencar, et al.
Cellular Microbiology|July 9, 2004
L-proline is essential for the intracellular differentiation of Trypanosoma cruziRenata R Tonelli, Ariel M Silber, Marinez Almeida-de-Faria, et al.
Plos Neglected Tropical Diseases|January 12, 2016
The Trypanosoma cruzi Protein TcHTE Is Critical for Heme UptakeMarcelo L Merli, Lucas Pagura, Josefina Hernández, et al.
International Journal of Biological Macromolecules|March 16, 2016
Resveratrol inhibits Trypanosoma cruzi arginine kinase and exerts a trypanocidal activityEdward A Valera Vera, Melisa Sayé, Chantal Reigada, et al.
Frontiers in Chemistry|November 16, 2020
Targeting L-Proline Uptake as New Strategy for Anti-chagas Drug DevelopmentLucía Fargnoli, Esteban A Panozzo-Zénere, Lucas Pagura, et al.
International Journal of Clinical Pharmacology Research|January 1, 1988
Pharmacokinetics of nilvadipine after single oral doses in healthy volunteersW K Cheung, D L Woodward, K Shin, et al.
International Journal of Nanomedicine|October 17, 2012
Application of magnetically induced hyperthermia in the model protozoan Crithidia fasciculata as a potential therapy against parasitic infectionsV Grazú, A M Silber, M Moros, et al.
Antimicrobial Agents and Chemotherapy|March 6, 2019
Pep5, a Fragment of Cyclin D2, Shows Antiparasitic Effects in Different Stages of the Trypanosoma cruzi Life Cycle and Blocks Parasite InfectivityChristiane Bezerra de Araujo, Loyze Paola de Lima, Simone Guedes Calderano, et al.
Journal of Clinical Pharmacology|November 1, 1988
Importance of oral dosing rate on the hemodynamic and pharmacokinetic profile on nilvadipineW K Cheung, L L Sia, D L Woodward, et al.
AAPS Pharmsci|December 14, 2001
CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial settingS McElroy, C Sachse, J Brockmoller, et al.
Pageof 15